Hui Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui Cao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Chao Zhang
Department of Gastrointestinal Surgery, Zibo Central Hospital, Shandong University, Zibo, Shandong, People's Republic of China
1 shared publication - Dai Shi
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
1 shared publication Feng Liu
Department of Thoracic Surgery Nanjing Chest Hospital Nanjing Jiangsu China
1 shared publication- Guihua Hou
Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China
1 shared publication Hanwen Zhou
School of Earth Science, China University of Geosciences, Wuhan 430074, PR China
1 shared publicationJie Jiang
Department of Thoracic Surgery Nanjing Chest Hospital Nanjing Jiangsu China
1 shared publication
Latest Publications
- 19 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4078
Silencing of ZNF610 suppresses cell proliferation and migration in lung adenocarcinoma
Zinc finger proteins (ZNFs) play a significant role in the initiation and progression of tumors. Nevertheless, the specific contribution of ZNF610 to lung adenocarcinoma (LUAD) remains poorly understood. This study sought is to elucidate the role of ZNF610 in LUAD. Transcript data of LUAD were obtained from The Cancer Genome Atlas Program (TCGA) database and processed via R program. The expression of ZNF610 was assessed in various cell lines. To compare the proliferative capacity of cells with or without ZNF610 silencing, CCK8, cell colony formation assay, and Celigo label‐free cell counting assay were employed. Furthermore, transwell migration and invasion assays were conducted to evaluate the migratory and invasive abilities of the cells. The expression levels of genes and proteins were assessed using quantitative real‐time polymerase chain reaction (qRT‐PCR) and western blot techniques. In different LUAD cells, the expression level of ZNF610 was found to be significantly higher in LUAD cells compared to MRC‐5 and BASE‐2B cells. Moreover, the silencing of ZNF610 resulted in a decrease in cell proliferation and migration abilities. Additionally, the apoptosis rate of cells increased upon silencing ZNF610. Notably, the proportion of cells in the G0/G1 phase increased, while the proportion of cells in the S phase decreased following ZNF610 silencing. Finally, β‐catenin and snail were identified as downstream targets of ZNF610 in cells. Our findings suggest that silencing ZNF610 could inhibit LUAD cell proliferation and migration, possibly through the downregulation of β‐catenin and snail.
- 19 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4078
Silencing of ZNF610 suppresses cell proliferation and migration in lung adenocarcinoma
Zinc finger proteins (ZNFs) play a significant role in the initiation and progression of tumors. Nevertheless, the specific contribution of ZNF610 to lung adenocarcinoma (LUAD) remains poorly understood. This study sought is to elucidate the role of ZNF610 in LUAD. Transcript data of LUAD were obtained from The Cancer Genome Atlas Program (TCGA) database and processed via R program. The expression of ZNF610 was assessed in various cell lines. To compare the proliferative capacity of cells with or without ZNF610 silencing, CCK8, cell colony formation assay, and Celigo label‐free cell counting assay were employed. Furthermore, transwell migration and invasion assays were conducted to evaluate the migratory and invasive abilities of the cells. The expression levels of genes and proteins were assessed using quantitative real‐time polymerase chain reaction (qRT‐PCR) and western blot techniques. In different LUAD cells, the expression level of ZNF610 was found to be significantly higher in LUAD cells compared to MRC‐5 and BASE‐2B cells. Moreover, the silencing of ZNF610 resulted in a decrease in cell proliferation and migration abilities. Additionally, the apoptosis rate of cells increased upon silencing ZNF610. Notably, the proportion of cells in the G0/G1 phase increased, while the proportion of cells in the S phase decreased following ZNF610 silencing. Finally, β‐catenin and snail were identified as downstream targets of ZNF610 in cells. Our findings suggest that silencing ZNF610 could inhibit LUAD cell proliferation and migration, possibly through the downregulation of β‐catenin and snail.
- 30 July 2021
- Published by Cambridge University Press (CUP) in Journal of Fluid Mechanics
- Vol. 923
Asymptotic behaviour of heat transfer in two-dimensional turbulent convection with high-porosity fluid-saturated media
We study the asymptotic behaviour of convective heat transfer for turbulent flows in high-porosity fluid-saturated media by two-dimensional high-resolution numerical simulation. The generalized Navier–Stokes equations for incompressible fluid flow and the heat transport equation in porous media at the representative element volume scale are solved by the lattice Boltzmann method, wherein the non-Darcian effects are taken into consideration. The asymptotic behaviour of the Nusselt number .
- 30 July 2021
- Published by Cambridge University Press (CUP) in Journal of Fluid Mechanics
- Vol. 923
Asymptotic behaviour of heat transfer in two-dimensional turbulent convection with high-porosity fluid-saturated media
We study the asymptotic behaviour of convective heat transfer for turbulent flows in high-porosity fluid-saturated media by two-dimensional high-resolution numerical simulation. The generalized Navier–Stokes equations for incompressible fluid flow and the heat transport equation in porous media at the representative element volume scale are solved by the lattice Boltzmann method, wherein the non-Darcian effects are taken into consideration. The asymptotic behaviour of the Nusselt number .
- Open Access
- 1 November 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (6) , 6413-6422
Radioimmunoimaging of 125I‑labeled anti‑CD93 monoclonal antibodies in a xenograft model of non‑small cell lung cancer
Lung cancer, especially non‑small cell lung cancer (NSCLC), is the most common malignant tumor associated with poor prognosis. Angiogenesis plays a vital role in NSCLC, and could be used in tumor staging and therapy evaluation. CD93 (C1q receptor) is reportedly a key regulator of tumor angiogenesis. In the present study, the efficacy and specificity of a 125I‑labeled CD93‑specific monoclonal antibody (125I‑anti‑CD93 mAb) in detecting NSCLC xenografts were analyzed, and the association between CD93 expression and 125I‑anti‑CD93 mAb uptake by tumors was evaluated. The targeting ability of 125I‑anti‑CD93 mAb enabled its rapid, continuous and highly specific accumulation in CD93‑expressing tumors in vivo. These results revealed the potential applicability of 125I‑anti‑CD93 mAb for non‑invasive imaging diagnosis of CD93‑positive NSCLC.
- 1 November 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (6) , 6413-6422
Open AccessRadioimmunoimaging of 125I‑labeled anti‑CD93 monoclonal antibodies in a xenograft model of non‑small cell lung cancer
Lung cancer, especially non‑small cell lung cancer (NSCLC), is the most common malignant tumor associated with poor prognosis. Angiogenesis plays a vital role in NSCLC, and could be used in tumor staging and therapy evaluation. CD93 (C1q receptor) is reportedly a key regulator of tumor angiogenesis. In the present study, the efficacy and specificity of a 125I‑labeled CD93‑specific monoclonal antibody (125I‑anti‑CD93 mAb) in detecting NSCLC xenografts were analyzed, and the association between CD93 expression and 125I‑anti‑CD93 mAb uptake by tumors was evaluated. The targeting ability of 125I‑anti‑CD93 mAb enabled its rapid, continuous and highly specific accumulation in CD93‑expressing tumors in vivo. These results revealed the potential applicability of 125I‑anti‑CD93 mAb for non‑invasive imaging diagnosis of CD93‑positive NSCLC.